Emergent BioSolutions (NYSE:EBS) Stock, Quote.Headers.trade-ideas

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Screenshot 2024-09-18 at 12.30.33 AM

Biotech

General

BVNKF

TNXP

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

movers image

CCCC

MEOH

MERC

Methanex, Merck And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Mpox virus

News

Health Care

Movers

Trading Ideas

The FDA has approved Emergent BioSolutions&#39; supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human safety data and animal studies.

Mpox Vaccine: Emergent BioSolutions&#39; Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

AEMD

APDN

CMRX

GOVX

MRNA

VRAX

US To Stay Committed In Bringing Mpox Outbreak Under Control

Rodman &amp; Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target

Legal

Emergent Biosolutions Has Entered Into An Agreement To Resolve The Previously Disclosed Securities Class Action Litigation, Emergent Will Pay $40M To Settle Claims

Morocco Records First Case Of Mpox

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) announced today that it was awarded a contract modification executing an option period by the&nbsp;Biomedical Advanced Research and Development Authority&nbsp;(BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the&nbsp;U.S. Department of Health and Human Services&nbsp;(HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga&#x2122; (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD).

Contracts

Emergent BioSolutions Awarded R&D Option valued At $41.9M For Continued Advanced Development And Procurement Of Ebanga Treatment For Ebola

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Monday.
Shares of Methanex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) fell sharply in today's <a href="https://www.benzinga.com/markets/equities/24/09/40769930/methanex-to-buy-ocis-international-methanol-business-for-2-05b-details">pre-market trading.</a>
Methanex disclosed that it has entered into a definitive agreement to acquire OCI Global‘s international methanol business for $2.05 billion.
Methanex shares tumbled 6.3% to $39.79 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>C4 Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) shares dipped 17% to $4.48 in pre-market trading. C4 Therapeutics will reveal preliminary CFT1946 monotherapy Phase 1 clinical data at ESMO Congress 2024.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) shares fell 5.4% to $4.90 in pre-market trading after gaining around 6% on Friday.</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell 4.8% to $112.23 in pre-market trading. Daiichi Sankyo and Merck&#8217;s Ifinatamab Deruxtecan showed response rates in extensive-stage small cell lung cancer in Phase 2 IDeate-Lung01 trial.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) shares declined 3.2% to $5.50 in pre-market trading. Adient will replace Mercer International in the S&amp;P SmallCap 600.</li>
<li>Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) shares fell 3.1% to $12.68 in pre-market trading.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 2.3% to $13.97 in pre-market trading after gaining over 4% on Friday.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares slipped 2.3% to $7.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40767657/s-p-500-records-largest-weekly-decline-since-march-2023-as-nvidia-google-tumble-fear-greed-index">S&amp;P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear &amp; Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Macro Economic Events

Economics

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523</a>
&nbsp;
Today, close to 100,000 mpox vaccine doses will arrive in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country. A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
These vaccines are part of the 215,000 MVA-BN&#xAE; <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244">vaccine doses</a> that the European Commission's Health Emergency Preparedness and Response Authority (HERA) procured and pledged to share to affected countries in Africa as an immediate response to the mpox outbreak.
Via Team Europe, an additional 351,500 of doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States, will be donated to the Africa CDC to distribute to affected countries. This brings the total number of vaccine doses donated from Team Europe to at least 566,500, which includes the above 215,000 doses that were donated by HERA in cooperation with the Bavarian Nordic pharmaceutical company.
EU support for the mpox outbreak
This initiative is part of a comprehensive set of EU actions put in place as part of the EU Global Health Strategy, which represents the external dimension of a strong European Health Union and is a key component of Global Gateway, to support partners in the rest of the world.
The Commission is actively coordinating the response of EU Member States to the mpox outbreak via regular meetings of the HERA Board and the Health Security Committee, which allows prompt coordination when dealing with health threats.
The Emergency Response Coordination Centre (ERCC) is in contact with EU Member States given that, if activated, the EU Civil Protection Mechanism (rescEU) can be used to channel mpox vaccines and therapeutics to countries in need. Specialised expertise, medical items and equipment could also be deployed based on these needs.
Under the Global Gateway investment strategy, the Commission is committed to advancing public health in Africa. The Commission has focused on strengthening health systems, securing pharmaceutical supply chains, and developing local manufacturing through investment in infrastructure and a supportive regulatory environment. An example of this is the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies (Mav+) and on Sustainable Health Security.
The European Centre for Disease Prevention and Control (ECDC) is supporting epidemiological work on the ground in the DRC, working with the Africa CDC to identify priority areas for mpox research, and is leading coordination of the Network of Major CDCs globally. HERA is also working with the Africa CDC with the aim of expanding access to mpox diagnostics and sequencing in the region, with a €9.4 million grant foreseen for early autumn.
The Commission has released €1 million in humanitarian aid to support care, prevention, epidemiological surveillance, risk communication and distribution of kits in the eastern DRC as well as €200,000 in Burundi to assist the Burundi Red Cross in preparing for and responding to the epidemic. Under the European Humanitarian Response Capacity (EHRC), in cooperation with the ECDC, two epidemiologists were deployed on 4 September to the DRC. In addition, the Commission provides regular humanitarian funding for surveillance programmes, including in Uganda and Kenya's camps and settlements and expertise to assist in the response.

Global

'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission

The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in additional cash to the balance sheet. Emergent also terminated its obligations under the senior term loan facility and the revolving credit facility under the Prior Credit Agreement.

Emergent Biosolutions Closed A New Credit Facility Agreement With Oak Hill Advisors For A Term Loan Of Up To $250M And Repaid Senior Term Loan Facility Dated October 15, 2018 Which Was Scheduled To Mature In May 2025

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 34.2% to $6.31 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares rose 17.62% to $10.48. The market value of their outstanding shares is at $549.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 14.96% to $0.19. The market value of their outstanding shares is at $2.2 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) stock increased by 14.95% to $4.06. The market value of their outstanding shares is at $5.3 million. </li>
<li>Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) shares moved upwards by 11.9% to $1.08. The market value of their outstanding shares is at $83.4 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares moved upwards by 11.41% to $8.49. The company's market cap stands at $307.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares declined by 48.3% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 27.95% to $0.98. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 15.18% to $0.95. The company's market cap stands at $17.5 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares decreased by 7.69% to $20.18. The market value of their outstanding shares is at $102.2 million. </li>
<li>Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares fell 7.5% to $265.51. The market value of their outstanding shares is at $34.0 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares declined by 6.42% to $1.75. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

BMEA

EKSO

LGMK

MLSS

NCNA

NUTX

SNPX

TOVX

VTAK

XCUR

12 Health Care Stocks Moving In Monday's Pre-Market Session

Macro Notification

BWVI

iShares MSCI Israel Capped Investable Market Index Fund

WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days

WHO Chief Tedros Says Received First Expression Of Interest For Emergency Use Listing From Mpox Diagnostics Manufacturer; WHO Officials Discuss Polio Vaccination Plan In Gaza, Confirm Applications From Bavarian Nordic And KM Biologics For Mpox Vaccines Emergency Use Listing, And Announce 230,000 Doses Available For Congo

Emergent BioSolutions shares are trading higher after the company announced that the FDA approved the supplemental Biologics License Application for the expansion of the indication for ACAM2000, to include prevention of mpox disease in individuals determined to be at high risk for mpox infection.

Thursday, the FDA approved Emergent BioSolutions Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) supplemental Biologics License Application (sBLA)&nbsp;for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40642197/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-f" rel="noreferrer noopener">risk for mpox infection</a>.
The approval is based on previously available human safety data and data from a well-controlled animal study in which the ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/08/40561898/who-seeks-135m-in-funding-to-fight-mpox-outbreak-can-be-controlled-and-can-be-stopped" rel="noreferrer noopener">WHO Seeks $135M In Funding To Fight Mpox: Outbreak &#8216;Can Be Controlled, And Can Be Stopped&#8217;</a>
ACAM2000 is a single-dose vaccine administered percutaneously via a bifurcated needle dipped into the vaccine solution, and the skin is pricked several times in the upper arm with a droplet of the vaccine.
The vaccine was first approved by the FDA in 2007 for active immunization to prevent smallpox disease in individuals at high risk for smallpox infection.
Mpox is an infectious disease endemic to central and west Africa caused by the double-stranded DNA mpox virus.
This approval follows <a target="_blank" href="https://www.benzinga.com/quote/ebs" rel="noreferrer noopener">Emergent&#8217;s</a> announcement&nbsp;that it filed an Expression of Interest with the World Health Organization for the WHO&#8217;s assessment of the ACAM2000 vaccine to be added as an Emergency Use Listing in connection with the mpox outbreak.
As part of its support for the response, Emergent announced that it will donate 50,000 doses of ACAM2000 for potential deployment in impacted countries in Central Africa.
ACAM2000 is the primary smallpox vaccine designated for use in a bioterrorism emergency, with doses having been supplied to the U.S. Strategic National Stockpile. ACAM2000 is also licensed in Canada, Australia, and&nbsp;Singapore&nbsp;and is currently stockpiled in the U.S. and internationally.
Reuters also noted that Nigeria received 10,000 doses of the mpox vaccine from the U.S. Agency for International Development, the first batch of the vaccine to reach the country, which has confirmed 40 cases with no fatalities.
Muyi Aina, executive director of the National Primary Health Care Development Agency, said, &#8220;We are aware that the vaccine is not exactly in surplus supply. I believe we&#8217;re getting 10,000 of the about 200,000 doses that are available globally.&#8221;
Price Action: At last check on Friday, EBS stock was up 15.70% at $10.31 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40632934/analysts-boosts-chewys-price-forecast-but-say-valuation-is-bit-stretched" target="_blank" rel="noreferrer noopener">Analyst Boosts Chewy&#8217;s Price Forecast But Says Valuation Is Bit Stretched</a>.</li>
</ul>
Mpox virus illustration via Shutterstock

Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Shares of MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40639636/mongodb-stock-rallies-after-strong-q2-results-upbeat-guidance"> issued strong guidance</a>.
MongoDB reported quarterly earnings of 70 cents per share, which beat the analyst consensus estimate of 49 cents by 42.86%. Quarterly sales came in at $478.1 million, which beat the consensus estimate by 3.03% and represents growth of 12.82% from the same period last year.
MongoDB shares jumped 15.2% to $283.07 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) gained 96.2% to $1.32 in pre-market trading after the company reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) rose 52.2% to $0.2894 in today's pre-market trading after the company in a Form4 filing disclosed that CEO Desheng Wang bought 302,100 shares of stock at an average price of $0.18 per share.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 29.4% to $11.54 in pre-market trading. Emergent BioSolutions&#8217; ACAM2000 vaccine gained the FDA nod for Mpox indication amidst rising public health crisis.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) gained 23% to $0.1283 in pre-market trading after dipping over 30% on Thursday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 16.8% to $5.63 in pre-market trading after the company was awarded a $116.9 million NASA contract to deliver six science and technology payloads to the Moon.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) gained 13.8% to $0.1855 in pre-market trading after declining 9% on Thursday.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) gained 8.8% to $76.00 in the pre-market trading session after the company reported its second-quarter financial results.</li>
<li>ADS-TEC Energy PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) gained 6.5% to $14.00 in pre-market trading.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6.5% to $117.90 in pre-market trading after the company reported stronger-than-expected results for its second quarter.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) shares declined 35.3% to $0.88 in pre-market trading after dipping 23% on Thursday.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares fell 27.1% to $75.60 in pre-market trading after the company reported first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>BioCardia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) fell 20.3% to $3.20 in pre-market trading. BioCardia shares jumped 83% on Wednesday after FDA cleared the company to market its Morph DNA Steerable Introducer product family.</li>
<li>XORTX Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRTX#NASDAQ">XRTX</a>) fell 13.3% to $2.34 in pre-market trading after surging over 130% on Thursday.</li>
<li>Ekso Bionics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 10.7% to $1.00 in pre-market trading. Ekso Bionics priced its $6 million underwritten public offering of 6m units with dual warrants.</li>
<li>Paltalk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALT#NASDAQ">PALT</a>) fell 10.4% to $4.89 in today's pre-market trading after gaining 14% on Thursday.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares declined 8.8% to $4.64 in pre-market trading. Innovative Eyewear shares jumped 54% on Thursday after the company announced that its Lucyd Lyte frames are now being sold on Target.com.</li>
<li>Duluth Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) shares fell 8.6% to $3.51 in pre-market trading. Duluth Holdings shares jumped around 19% on Thursday after the company reported better-than-expected second-quarter sales results.</li>
<li>Autozi Internet Technology (Global) Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares dipped 6.9% to $2.70 in pre-market trading after gaining over 10% on Thursday. Autozi Internet Technology (Global) announced the closing of initial public offering.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) declined 6.4% to $344.03 in pre-market trading after the company reported weaker-than-expected results for its second quarter and cut its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Pre-Market Outlook

Markets

ADSE

BCDA

BNRG

DELL

DLTH

ESTC

FCUV

LUCY

LUNR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MRVL

PALT

ULTA

XRTX

Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Emergent BioSolutions&nbsp;announced that the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) has approved the supplemental Biologics License Application (sBLA)&nbsp;for the expansion of the indication for ACAM2000&reg;, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000&reg;&nbsp;vaccine was shown to be effective in protecting against mpox virus exposure.

Reported Earlier, Emergent BioSolutions' ACAM2000 Vaccine Gains FDA Nod For Mpox Indication Amidst Rising Public Health Crisis

CDC Says Clade I Mpox Outbreak Originating In Central Africa; Risk Of Mpox Coming Into U.S. Is Low; No Cases Of Clade I Mpox Have Been Reported In The U.S. At This Time; Best Protection Against Mpox Is Two Doses Of Jynneos Vaccine If Eligible; Working With Other U.S. Government Agencies & Partners On Strategy For Vaccination In Democratic Republic Of Congo

<a href="https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/">https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/</a>
&nbsp;
One case of mpox has been reported at the Clark County Detention Center, according to the Metropolitan Police Department.
While police were unable to confirm which date the case was reported, Metro said it was during the week of August 19.
The person with mpox, which is formerly known as monkeypox, is no longer in custody, police said Tuesday, adding that there were no other reported cases.
&nbsp;
According to the Centers for Disease Control, the virus is part of the same family as the virus that causes smallpox. Symptoms commonly include a rash that scabs before healing.
The disease can be spread between animals and people, the <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">CDC</a> website reads. It is spread through skin-to-skin contact.

Reported August 27, 2024 'Mpox Case Reported At Clark County Detention Center' - Las Vegas Review-Journal

The World Health Organization announced a new strategic preparedness and response plan Monday in the fight against mpox, two weeks after declaring a public health emergency<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> on the outbreak.</a>
What Happened: The WHO announced a new plan in its fight against the outbreak of mpox. The plan comes as several companies are<a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on"> ramping up efforts</a> to launch or increase output of mpox vaccines and treatment options.
The <a href="https://www.who.int/news/item/26-08-2024-global-strategic-preparedness-and-response-plan-launched-by-who-to-contain-mpox-outbreak">plan </a>calls for $135 million in funding for the WHO response and for member states and partners. Among the partners are communities, researchers and the Africa Centres for Disease Control and Prevention.
Funding will help with surveillance, prevention, readiness and the response to fight outbreaks of mpox, the WHO said.
The WHO said it will take part in strategic vaccination efforts to focus on high-risk individuals, which includes health care workers and those with close contact to recent cases.
"The mpox outbreaks in the Democratic Republic of the Congo and neighboring countries can be controlled, and can be stopped," WHO Director-General Dr. Tedros Adhanom Ghebreyesus said. 
"Doing so requires a comprehensive and coordinated plan of action between international agencies and national and local partners, civil society, researchers and manufacturers, and our Member States."
A virtual scientific conference will be held on Aug. 29 and Aug 30 to share mpox research and outbreak control goals from the WHO, Africa CDC and the National Institute of Allergy and Infectious Diseases.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str">Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain</a>
Why It's Important: The six-month plan is viewed as the critical step in stopping mpox outbreaks from spreading further or faster.
On Monday, Germany announced it will donate 100,000 mpox vaccine doses from its stockpile to help with the outbreak prevention, as reported by Reuters. Germany will keep a minimum stock of mpox vaccines, the report said. 
There have been 3,326 confirmed cases of mpox in Africa in 2024, with 590 deaths across 12 countries, according to the Africa Centres for Disease Control and Prevention, as <a href="https://thehill.com/policy/healthcare/4847877-who-releases-mpox-outbreak-plan/">reported </a>by The Hill. A total of 17,979 suspected mpox cases have been reported. 
Shares of companies that have mpox vaccines or treatments have been highly volatile over the last two weeks. The list includes Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and Emergent Biosolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), both of which have WHO-recommended vaccines
GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) have also been highly volatile. GeoVax has a mpox vaccine in clinical development. SIGA Technologies has Tpoxx, which is a treatment for mpox.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine">Tonix Pharma Collaborates With World&#8217;s Largest Vaccine Manufacturer For Mpox Vaccine</a></li>
</ul>
Illustration via Shutterstock.

BVNRY

SIGA

WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'

Spain and Germany to donate mpox vaccine doses to Africa

Emergent Biosolutions (EBS) just unveiled an update. Emergent BioSolutions Inc. recently announced that the U.S. FDA has approved the expansion of ...

Emergent BioSolutions Gains FDA Nod and WHO Evaluation

Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox

UNICEF issues emergency tender to secure mpox vaccines

Emergent Biosolutions (EBS) has issued an update. Emergent BioSolutions Inc. secured a $250 million term loan on August 30, 2024, with lenders and ...

Emergent BioSolutions Secures $250M Loan and Adjusts Equity

Africa-based Aspen reportedly in talks for mpox vaccine production

Emergent Bio slips after financing deal

Bavarian Nordic stock slides on Moderna mpox vaccine study

Morocco reports first mpox case amid ongoing global outbreak

Emergent Bio to pay $40M to settle class action lawsuit

APNHF

APNHY

CODX

RHHBF

RHHBY

Earnings

Press Releases

Emergent BioSolutions Reports Second Quarter 2024 Financial Results

Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Financing

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Emergent BioSolutions

Emergent BioSolutions (EBS) Forecast

Emergent BioSolutions (NYSE:EBS) Stock, Quote.Headers.trade-ideas